Medical/Pharmaceuticals News & Press Release Distribution

Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 2024 ESMO Congress

SAN FRANCISCO and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabol...

2024-09-18 08:00 3705

Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress

SAN FRANCISCO and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...

2024-09-18 08:00 3727

MedAdvisor Solutions Launches Pharmacy Advisory Group to Empower and Expand the Role of the Pharmacist

Industry leaders collaborate to bring innovative approaches to evolving pharmacy needs CAMBERWELL, Australia, Sept. 18, 2024 /PRNewswire/ -- MedAdvisor Solutions, a global leader in pharmacy-driven patient engagement solutions, announced today the launch of its Pharmacy Advisory Group. The colla...

2024-09-18 06:00 2574

Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®

MELBOURNE, Australia, Sept. 18, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET[1] ag...

2024-09-18 05:00 2041

Datasea's New 5G AI Multimodal Agreements Have Already Generated $9.0 Million of 5G-AI Services

Agreements Boost Fiscal 2025 Revenue and Expand Datasea's 5G Application Market Positioning inChina BEIJING, Sept. 17, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based company focused on innovative high-tech acoustics and 5G-Artificial Intelligence ("A...

2024-09-17 21:45 2311

Zoetis to Introduce First Cartridge-Based AI-Powered Haematology Analyser

* Zoetis is introducing Vetscan® OptiCell™ to Australia as it continues to transform diagnostics with its suite of integrated products and services * The new haematology analyser offers innovative AI-powered technology for CBC analysis, providing lab quality accuracy1 at the point of care * ...

2024-09-17 21:00 2157

Respiree teams up with Roche Diagnostics in APAC to introduce a new simplified way of hospital patient monitoring

With this collaboration, Respiree's patient monitoring solution will be made available for healthcare professionals in APAC through a pilot program using Roche's bloodglucose monitoring system. The goal is to simplify clinical workflows and augment diagnostic and monitoring capabilities, leading ...

2024-09-17 20:45 2665

Respiree teams up with Roche Diagnostics in APAC to introduce a new simplified way of hospital patient monitoring

Metabolon Expands Integrated Bioinformatics Platform to Include Advanced Statistical Analysis Tool

New tool plays a critical role in supporting complex multiomic research initiatives byhelping scientists design and execute customized statistical analyses MORRISVILLE, N.C., Sept. 17, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide va...

2024-09-17 20:15 1599

See-Mode Technologies Receives FDA Clearance for Thyroid Ultrasound AI Analysis and Reporting Software

MELBOURNE, Australia, Sept. 17, 2024 /PRNewswire/ -- See-Mode Technologies, a global innovator in AI for ultrasound imaging, today announced the receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their thyroid ultrasound analysis and reporting software. See-Mode's A...

2024-09-17 20:00 2157

Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity

- ASC30 is the first and only small molecule GLP-1 receptor (GLP-1R) agonist that can be dosed once-monthly subcutaneously and once-daily orally to treat obesity - ASC30 is two- to threefold more potent, in vitro, than orforglipron and stimulated significantly greater insulin secretion when comp...

2024-09-17 18:25 3501

Subgroup Analysis from Pivotal WU-KONG1B Study Exhibits Robust Efficacy of Sunvozertinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations Across Different Baseline Characteristics

Results of subgroup analysis from the pivotal WU-KONG1B study in relapsed or refractory NSCLC with EGFR exon20ins presented at ESMO 2024 * Sunvozertinib demonstrated promising anti-tumor efficacy, regardless of EGFR exon20ins region classification, race, region, baseline brain metastasis, prio...

2024-09-17 15:47 2608

WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024

BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- WestGene Biopharma, a leading innovator in mRNA therapeutics, presented the latest clinical data for its EBV-positive tumour mRNA vaccine, WGc-043, during a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. ...

2024-09-17 00:01 1945

WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024

TraceLink Co-Founder and SVP of Supply Network Products Lucy Deus Named Recipient of 2024 Women in Supply Chain Award

Deus was recognized in the Trailblazers category, which honors female leaders who continue to pave the way for future women in logistics BOSTON, Sept. 16, 2024 /PRNewswire/ -- TraceLink, the only no-code platform for intelligent orchestration of end-to-end supply chains, proudly announces thatLu...

2024-09-16 23:34 2152

Sirtex Medical Announces Certification of SIR-Spheres® Y-90 Resin Microspheres According to Medical Device Regulation (EU) 2017/745 and European Launch of the Innovative SIROS™ Delivery System

Sirtex brings an innovative liver cancer treatment delivery system to Europe, enhancing options for physicians and their patients. WOBURN, Mass., Sept. 16, 2024 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, today announced that it has re...

2024-09-16 21:00 2107

Argon Medical Launches CLEANER Vac™ Thrombectomy System to Remove Blood Clot in the Peripheral Venous Vasculature

PLANO, Texas, Sept. 16, 2024 /PRNewswire/ -- Argon Medical Devices, a leading provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announced the launch of the CLEANER Vac™ Thrombectomy System for the removal of bl...

2024-09-16 20:47 2294

Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment

BEIJING, Sept. 16, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that Guangzhou Concord Cancer Center ("Guangzhou H...

2024-09-16 20:00 2946

Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer Treatment

NANJING, China, Sept. 16, 2024 /PRNewswire/ -- Vazyme (688105.SH), a leading life science technology company, significantly contributed to groundbreaking research published in Science Magazine through its innovative products. The study, which focuses on how mutant IDH1 inhibition activates tumor ...

2024-09-16 19:00 2503

Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer Treatment

Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024

* In patients with non-small cell lung cancer (NSCLC) or melanoma who had acquired resistance to checkpoint inhibitors (CPIs), ATN-037 in combination with KEYTRUDA®(pembrolizumab) demonstrated an overall response rate (ORR) of 21.1% and a disease control rate (DCR) of 89.5%. * Data from the...

2024-09-16 18:00 2846

Akeso's Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024

HONG KONG, Sept. 16, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) published the phase 2 results from its ivonescimab in combination with chemotherapy as a first-line (1L) treatment for triple-negative breast cancer (TNBC). The prelimina...

2024-09-16 15:35 5212

Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024

SUZHOU, China, Sept. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 were presented at the 2024 European Society for Medical Oncology Congress (ESMO Congress 202...

2024-09-16 13:03 2682